Preliminary results from an ongoing phase 2, open-label, multicenter, single-arm study assessing an every-4-week dosing schedule of mogamulizumab in patients with cutaneous t-cell lymphoma
Authors
Scarisbrick, J.Querfeld, C.
Akilov, O.
Bagot, M.
Córdoba, R.
Cowan, Richard
García-Sancho, A. M.
Geskin, L. J.
Huen, A. O.
Jadwani, J.
Liu, Y.
Zhao, H.
Morris, S.
Ortiz-Romero, P. L.
Patel, A.
Pinter-Brown, L. C.
Pujol, R. M.
Quaglino, P.
Saba, N. S.
Vuppugalla, R.
Kim, Y. H.
Affiliation
Christie Hospital Foundation NHS Trust, University of Manchester, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Scarisbrick J, Querfeld C, Akilov O, Bagot M, Córdoba R, Cowan R, et al. Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S30-S1. PubMed PMID: WOS:001330761900064. English.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114402Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114402Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114402